Early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) significantly enhance survival of severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: results of the CAMELIA clinical trial

Blanc, François-Xavier; Sok, Thim; Laureillard, Didier; Borand, Laurence; Rekacewicz, Claire; Nerrienet, Eric; Madec, Yoann; Marcy, Olivier; Chan, Sarin; Prak, Narom; Kim, Chindamony; Kim Lak, Khemarin; Hak, Chanroeurn; Dim, Bunnet; Im Sin, Chhun; Sun, Sath; Guillard, Bertrand; Sar, Borann; Vong, Sirenda; Fernandez, Marcelo; Fox, Lawrence; Delfraissy, Jean-François; Goldfeld, Anne E

doi:10.1186/1753-6561-5-S1-O11

BMC Proceedings

Article metrics
Last updated: Fri, 19 Apr 2024 1:21:37 Z

Early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) significantly enhance survival of severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: results of the CAMELIA clinical trial

Access & Citations

2086

Article Accesses
0

Web of Science
17

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1753-6561

Contact us

Submission enquiries: supplements@biomedcentral.com
General enquiries: ORSupport@springernature.com